Belite Bio - ADR opened higher at $157.31, compared with its previous close of $155.94. In the last trading session, the stock traded between $149.78 and $170.89. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Belite Bio - ADR is now worth
$ 1,605.48
Giving a profit of
$ 1,505.48 (1505.48%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
+$14.08 (+9.03%)
Day High
$170.89
Day Low
$149.78
Day Open
$157.31
Prev Close
$155.94
Volume
4,72,772
1W Return
10.54%
1M Return
7.00%
3M Return
-3.87%
6M Return
11.88%
1Y Return
60.76%
Market Cap ($ Mn)
6,847
PE Ratio
-
PB Ratio
7.86
PEG Ratio
-
ROE
-25.90%
ROCE
-28.16%
EPS (TTM)
$-0.71
1 Week
10.54%
1 Month
7.00%
3 Months
-3.87%
6 Months
11.88%
9 Months
-2.88%
Belite Bio Q3 Results: Loss per share narrows to $(0.65), beats estimate
Loss per share of $(0.65) beat analyst estimate of $(0.80). Earnings performance exceeded consensus by 18.75%. Loss per share remained unchanged from the same period last year.
TodayBelite Bio to trade on Nasdaq Global Select Market from Oct 19
Belite Bio approved for transfer to Nasdaq Global Select Market. Trading begins October 19, 2026, under ticker BLTE. Move signifies meeting stringent financial and liquidity standards. Aims to enhance institutional investor visibility and shareholder liquidity.
24 days agoBelite Bio files MAAs for tinlarebant via Access Consortium pathway
Belite Bio filed Marketing Authorization Applications for tinlarebant in Singapore, UK, and Switzerland via the Access Consortium framework. Tinlarebant would be the first approved treatment for Stargardt disease type 1 in these three markets if successful. Submissions run parallel to NDAs in the U.S. (PDUFA date Feb 12, 2027) and Japan (Sakigake designation). The drug targets ABCA4 gene mutations causing progressive vision loss by reducing bisretinoid accumulation.
29 days agoBelite Bio to present Phase 3 tinlarebant data at Euretina conference
Belite Bio to present Phase 3 DRAGON study results at Euretina in Vienna. FDA accepted new drug application for tinlarebant with priority review in August 2026. PDUFA date set for February 12, 2027, for STGD1 treatment approval. Tinlarebant holds Breakthrough Therapy and Orphan Drug designations in US.
1mo agoBelite Bio rises 9.6% as Canaccord sets $303 target on tinlarebant approval
Canaccord Genuity initiates Belite Bio with a Buy rating and $303 price target. FDA granted Priority Review for tinlarebant with a PDUFA date of Feb 12, 2027. Analyst projects ~$6 billion in US sales by 2033 and ~$700 million peak in Japan. Shares rose 9.63% to $187.56, approaching the 52-week high of $200.00. Phase 3 data for geographic atrophy expected in Q3 2027 serves as next catalyst.
2mo agoBelite Bio to host virtual commercial day for tinlarebant ahead of FDA decision
Belite Bio to host virtual commercial day on September 2, 2026. FDA granted Priority Review for tinlarebant NDA in STGD1. Prescription Drug User Fee Act date set for February 12, 2027. Session covers prelaunch strategies and commercial opportunity.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Belite Bio - ADR is now worth
$ 1,605.48
Giving a profit of
$ 1,505.48 (1505.48%)
Note: Past profits do not guarantee future returns.
